Product Information
ETODOLAC 300 MG CAPSULE is a generic product labeled by Taro Pharmaceuticals U.S.A. Inc., priced at $0.4156 per EA under NDC 51672401701. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Apr 30, 1998. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Taro Pharmaceuticals U.S.A. Inc.NDC
51672401701
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ETODOLACApproval Type
Generic (ANDA)
FDA Application
ANDA075078FDA Approved
4/30/1998
TE Code
AB
On Market Since
4/30/1998
Pharmacological Classes
Price Statistics
The NADAC for ETODOLAC 300 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 66.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4156 per EA |
|---|---|
| All-time high | $1.3066 (Jul 15, 2015) |
| All-time low | $0.2659 (Aug 21, 2024) |
| 52-week high | $0.4156 |
| 52-week low | $0.3166 |
| Median price | $0.6863 |
| Average price | $0.7588 |
| Largest weekly change | +85.5% (Aug 17, 2022) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Taro Pharmaceuticals U.S.A. Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Etodolac market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ETODOLAC 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for ETODOLAC 300 MG CAPSULE, manufactured by Taro Pharmaceuticals U.S.A. Inc., is $0.4156 per EA (NDC 51672401701), effective Sep 30, 2026.
How has the price of ETODOLAC 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for ETODOLAC 300 MG CAPSULE has declined 66.7%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ETODOLAC 300 MG CAPSULE?
Since Nov 28, 2013, the NADAC for ETODOLAC 300 MG CAPSULE has ranged from a low of $0.2659 (Aug 21, 2024) to a high of $1.3066 (Jul 15, 2015), with a median of $0.6863 per EA.
Are there cheaper alternatives to ETODOLAC 300 MG CAPSULE?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ETODOLAC 300 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures ETODOLAC 300 MG CAPSULE?
ETODOLAC 300 MG CAPSULE (NDC 51672401701) is labeled by Taro Pharmaceuticals U.S.A. Inc., and CMS classifies it as a generic product.